Clinical Trial

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND

Study acronym: TRACE-BEYOND
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The benefit-risk profile of thrombolysis for acute ischemic strokes beyond 24 hours has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to assess the safety and efficacy of tenecteplase (0.25mg/kg, max 25mg) versus standard medical treatment in acute ischemic stroke due to intracranial vessel occlusion between 24-72 hours of symptom onset (including wake-up stroke and unwitnessed stroke).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-24; most recent amendment 2026-03-27.
Status change: Not Yet Recruiting → Recruiting 2025-11-17
Trial Details
NCT Number NCT06954155
Lead Sponsor Beijing Tiantan Hospital
Conditions Stroke
Enrollment 330 participants
Start Date 2025-05-30
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-01